Patents Assigned to KeMyth Biotech Co., Ltd.
  • Antibiotic testing and screening system
    Patent number: 10760110
    Abstract: The present invention provides a platform technology for testing, screening, selecting and evaluating antibiotics by using genetically engineered strains with identified, individual or combined, resistance mechanisms, prepared from fully susceptible clinical isolates. This antibiotic testing and screening system of the present invention can efficiently and effectively evaluate antibiotics against specified resistance mechanisms in vitro and in vivo, and is suitable on the novel antibiotic development in against multidrug-resistant bacteria.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: September 1, 2020
    Assignee: KeMyth Biotech Co., Ltd.
    Inventors: Yu-Kuo Tsai, Leung-Kei Siu
  • TREATMENT OF DIABETES, TOLL-LIKE RECEPTOR 4 MODULATORS AND METHODS FOR USING THE SAME
    Publication number: 20190359658
    Abstract: The present invention relates to treatment of diabetes, toll-like receptor 4 (TLR-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (PLY peptide) which is effective in treatment of diabetes. In addition, the PLY peptide of the present invention is a TLR-4 antagonist and thus can be used in the treatment of a disease or condition associated with TLR-4 activation. The present invention also provides treatment of diabetes with a TLR-4 antagonist.
    Type: Application
    Filed: March 18, 2019
    Publication date: November 28, 2019
    Applicant: KeMyth Biotech Co., Ltd.
    Inventors: Leung-Kei Siu, Pele Choi-Sing Chong, Feng-Yee Chang, Chih-Hsiang Leng
  • Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same
    Patent number: 10287328
    Abstract: The present invention relates to treatment of diabetes, toll-like receptor 4 (TLR-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (PLY peptide) which is effective in treatment of diabetes. In addition, the PLY peptide of the present invention is a TLR-4 antagonist and thus can be used in the treatment of a disease or condition associated with TLR-4 activation. The present invention also provides treatment of diabetes with a TLR-4 antagonist.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: May 14, 2019
    Assignee: KeMyth Biotech Co., Ltd.
    Inventors: Leung-Kei Siu, Pele Choi-Sing Chong, Feng-Yee Chang, Chih-Hsiang Leng
  • ANTIBIOTIC TESTING AND SCREENING SYSTEM
    Publication number: 20180245125
    Abstract: The present invention provides a platform technology for testing, screening, selecting and evaluating antibiotics by using genetically engineered strains with identified, individual or combined, resistance mechanisms, prepared from fully susceptible clinical isolates. This antibiotic testing and screening system of the present invention can efficiently and effectively evaluate antibiotics against specified resistance mechanisms in vitro and in vivo, and is suitable on the novel antibiotic development in against multidrug-resistant bacteria.
    Type: Application
    Filed: February 23, 2018
    Publication date: August 30, 2018
    Applicant: KeMyth Biotech Co., Ltd.
    Inventors: Yu-Kuo Tsai, Leung-Kei Siu
  • TREATMENT OF DIABETES, TOLL-LIKE RECEPTOR 4 MODULATORS AND METHODS FOR USING THE SAME
    Publication number: 20170260241
    Abstract: The present invention relates to treatment of diabetes, toll-like receptor 4 (TLR-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (PLY peptide) which is effective in treatment of diabetes. In addition, the PLY peptide of the present invention is a TLR-4 antagonist and thus can be used in the treatment of a disease or condition associated with TLR-4 activation. The present invention also provides treatment of diabetes with a TLR-4 antagonist.
    Type: Application
    Filed: February 24, 2017
    Publication date: September 14, 2017
    Applicants: KeMyth Biotech Co., Ltd.
    Inventors: Leung-Kei Siu, Pele Choi-Sing Chong, Feng-Yee Chang, Chih-Hsiang Leng